ReviewRedox biology2026
Reactive oxygen species in thoracic aortic dissection: Insights into mechanisms and disease progression.
Review in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thoracic aortic dissection (TAD) is a life-threatening vascular disorder defined by disruption of the aortic intima and progressive degeneration of the medial layer, accompanied with false lumen formation. Accumulating evidence supports a pivotal contribution of reactive oxygen species (ROS) to the initiation and progression of TAD, primarily by driving oxidative stress-associated cellular events. This review summarizes the ROS production mechanism in TAD pathogenesis and discusses how ROS contribute to disease progression through oxidative stress, inflammatory signaling, and structural degradation of the aortic wall. We further examine the multilayered regulatory networks governing ROS activity, including transcriptional and epigenetic regulation, metabolic reprogramming, that collectively shape vascular dysfunction in TAD. In addition, we discuss potential ROS-targeted therapeutic treatments, including inhibition of ROS-generating enzymes, enhancement of antioxidant systems, modulation of downstream signaling pathways, and correction of metabolic reprogramming. We also critically discuss the translational limitations of current redox-targeted approaches, emphasizing the lack of disease specificity, limited clinical validation, and the challenge of selectively suppressing pathological ROS. This review aims to synthesize current evidence linking ROS dysregulation to the onset and progression of TAD, while highlighting emerging therapeutic strategies and their potential clinical implications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.